<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578773</url>
  </required_header>
  <id_info>
    <org_study_id>C-05-38</org_study_id>
    <nct_id>NCT00578773</nct_id>
  </id_info>
  <brief_title>A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea</brief_title>
  <official_title>Safety and Efficacy of a Topical Otic Formulation in the Treatment of Peri-Operative Tube Otorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an otic formulation is safe and effective in&#xD;
      treating peri-operative tube otorrhea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to cessation of otorrhea as recorded by the parent or guardian via a patient diary</measure>
    <time_frame>From baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cures at each visit</measure>
    <time_frame>From baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of otorrhea at each visit</measure>
    <time_frame>From baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Acute Otitis Media</condition>
  <arm_group>
    <arm_group_label>Moxidex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxidex otic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin otic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TT only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tympanostomy tubes only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxidex otic solution</intervention_name>
    <description>4 drops into the infected ear(s) twice daily (morning and evening) for 7 days</description>
    <arm_group_label>Moxidex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin otic solution</intervention_name>
    <description>4 drops into the infected ear(s) twice daily (morning and evening) for 7 days</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tympanostomy tubes</intervention_name>
    <description>Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children</description>
    <arm_group_label>Moxidex</arm_group_label>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_label>TT only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  6 months to 12 years old&#xD;
&#xD;
          -  Diagnosed with recurrent acute otitis media or chronic otitis media with effusion&#xD;
&#xD;
          -  Must be first set of ear tubes.&#xD;
&#xD;
          -  Patient may not have had any other previous otologic-related surgery.&#xD;
&#xD;
          -  Ear tube may not be silver oxide, silver salt, t-type tube or long-shafted tube&#xD;
&#xD;
          -  Patient may not have existing perforation of the eardrum.&#xD;
&#xD;
          -  Patient must not require another surgical procedure other than myringotomy and tube&#xD;
             insertion.&#xD;
&#xD;
          -  Patient may not be a menarchal female&#xD;
&#xD;
          -  Diabetic patients are not eligible&#xD;
&#xD;
          -  Patient may not have any disease or condition that would negatively affect the conduct&#xD;
             of the study&#xD;
&#xD;
          -  Patient may not require any other systemic antimicrobial therapy during the study.&#xD;
&#xD;
          -  Patient must meet certain medication washouts to be eligible&#xD;
&#xD;
          -  Analgesic use (other than acetaminophen) is not allowed&#xD;
&#xD;
          -  Patient may not be pre-disposed to neurosensory hearing loss&#xD;
&#xD;
          -  Other protocol-defined inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&#xD;
&#xD;
          -  Other protocol-defined exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Contact Alcon Call Center</last_name>
    <role>Study Director</role>
    <affiliation>1-888-451-3937</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <disposition_first_submitted>November 28, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 29, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 3, 2012</disposition_first_posted>
  <last_update_submitted>November 29, 2012</last_update_submitted>
  <last_update_submitted_qc>November 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ear tubes</keyword>
  <keyword>ear infection</keyword>
  <keyword>ear drops</keyword>
  <keyword>ear tube surgery</keyword>
  <keyword>acute otitis media</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

